Cybin (CYBN) announced that its clinical trial application has been approved by the Irish Medicines Board, acting as the reference Member state, to initiate the EMBRACE study in Ireland, Poland, and Greece. EMBRACE is the second pivotal study in PARADIGM, the Company’s Phase 3 multinational program evaluating CYB003, a proprietary deuterated psilocin analog. The company also recently announced approval from the Medical and Healthcare products Regulatory Agency to commence EMBRACE in the United Kingdom.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Cybin Secures European Approval for EMBRACE Study in Major Depressive Disorder
- Cybin CEO to Speak at Canaccord Genuity Growth Conference
- Cybin files $1B mixed securities shelf
- Cybin Inc. Schedules Virtual Annual General Meeting for August 2025
- Psychedelic: Clearmind expands trial for Alcohol Use Disorder